Tag Archives: genomics personalized medicine

Rayno Life Science Stocks: Be An Investor Not A Trader…Update-1

Update-1 …After 1.94% NASDAQ Sell-Off All three market indices got crushed today with a downdraft attributed to ending of QE, rising i rates in 2015, a rising dollar and just plain profit taking. A 3.8% hit on Apple (AAPL) did not help support the QQQ which also holds many large cap biotech stocks.The healthcare sector […]

Leave a comment Continue Reading →

Biotech Rally Update… up 12.9% in 30 Days: ACHN, CLDX, FBT, KPTI

Rayno Biopharmaceutical Stocks- Including New Picks Another great day for biotech with most Rayno stocks in a rally mode with a bit of profit taking on Gilead Sciences(GILD) down 1%. Notable movers up on our core picks are: Alkermes (ALKS), Amgen (AMGN), Ariad (ARIA), Regeneron (REGN) and Vertex (VRTX).Our top small cap pick Achillion (ACHN) […]

Comments Off Continue Reading →

Green Day with Rayno Biopharmaceutical Stocks Up >2%

Some Huge Moves Today Brings Hope For Summer Rally ETFs Up: FBT $83 up 2.58%, IBB $254.78 up 1.14%, XBI $148.9 up 3.28%. Rayno Large Cap Portfolio: up 14,4% YTD with Biogen Idec(BIIB) and Gilead (GILD) leaders; near July highs. Virtually everything is up but big winners are: Ariad (ARIA $6.17) up 9.98%, Pharmacyclics (PCYC $124.75) […]

Comments Off Continue Reading →

No Summer Doldrums In Biotech Today … PBYI…Update-1

Update 7/23 Biogen Idec (BIIB) Soars 11% on Earnings EPS at $3.49 vs est $2.83; Sales of MS drugs were $2.42B vs $1.72B last year. Our large cap portfolio is now up 15% YTD with less risk than mid and small caps. One analyst thinks PBYI will be acquired but watch out with a market […]

Comments Off Continue Reading →

Rayno Diagnostics and Tools Stocks: GHDX, ILMN, QGEN, RGDX.

Rayno Life Science Stocks Focused on Genetic Tests and Biomarkers We have been writing about molecular diagnostics and tools stocks for over 5 years. Here is the summary of our Portfolio. Yesterday we provided an update from BIO 2014  on personalized medicine and genetic tests. Many genetic tests are not FDA approved usually called LDTs […]

Comments Off Continue Reading →

BIO 2014 Update #1 Personalized Medicine-Megatrend Momentum Continues

Challenges Ahead But Sequencing Is  A Driver We first reported on Personalized Medicine in 2010 with an article on the importance of  Biomarkers for exploiting breakthroughs in the molecular basis of disease. The BIO 2014 Personalized Medicine and Diagnostics Forum provided full day coverage offering insights as to how the science driving personalized medicine is reshaping […]

Comments Off Continue Reading →